Evidence map›Paper›PMID 41372446›Full record

ArticleNature nanotechnology2026

Cell-free immuno-profiling on a genetically programmed biochip.

Aurore Dupin, Ohad Vonshak, Valerie Nir, Maya Levanon, Noa Avidan, Yiftach Divon, Steve Peleg, Seth Thompson, Vincent Noireaux, Shirley S Daube and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Aurore Dupin *Department of Chemical and Biological Physics, Weizmann Institute, Rehovot, Israel. aurore.dupin@weizmann.ac.il.ORCID http://orcid.org/0000-0002-1372-1144
Ohad Vonshak *Department of Chemical and Biological Physics, Weizmann Institute, Rehovot, Israel.ORCID http://orcid.org/0000-0003-1437-3556
Valerie NirDepartment of Chemical and Biological Physics, Weizmann Institute, Rehovot, Israel.
Maya LevanonDepartment of Chemical and Biological Physics, Weizmann Institute, Rehovot, Israel.ORCID http://orcid.org/0009-0002-2154-2012
Noa AvidanDepartment of Chemical and Biological Physics, Weizmann Institute, Rehovot, Israel.ORCID http://orcid.org/0000-0003-3198-9897
Yiftach DivonDepartment of Chemical and Biological Physics, Weizmann Institute, Rehovot, Israel.
Steve PelegDepartment of Chemical and Biological Physics, Weizmann Institute, Rehovot, Israel.
Seth ThompsonSchool of Physics and Astronomy, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0003-1713-223X
Vincent NoireauxSchool of Physics and Astronomy, University of Minnesota, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0002-5213-273X
Shirley S DaubeDepartment of Chemical and Biological Physics, Weizmann Institute, Rehovot, Israel. shirley.daube@weizmann.ac.il.ORCID http://orcid.org/0000-0002-5566-9313
Roy H Bar-ZivDepartment of Chemical and Biological Physics, Weizmann Institute, Rehovot, Israel. roy.bar-ziv@weizmann.ac.il.ORCID http://orcid.org/0000-0002-7583-7900

Funding

European Molecular Biology Organization (EMBO) ALTF 131-2020Israel Science Foundation (ISF) 3435/24United States-Israel Binational Science Foundation (BSF) 2022385U.S. Department of Defense (United States Department of Defense) W911NF2010119
6 · The paper itself

Abstract

Cell-free synthetic biology approaches offer biosafe, low-cost and versatile genetic tools to advance therapeutic research and development. Measuring the antibody response to a range of target and off-target proteins is essential for deep immuno-profiling of therapeutic antibodies and individual patient immune responses. Here we extend a previously developed microfluidic-free biochip platform to quantitatively reconstitute interactions of cell-free synthesized antigens with antibodies in miniaturized, photolithographically patterned compartments from localized gene brushes. This creates a continuous density gradient of antigens displayed on the surface, generating multiple antibody binding curves, one in each single nanolitre-volume compartment for affinity determination. We used SARS-CoV-2 antigens to profile the specificity and affinity of monoclonal antibodies to more than 30 viral epitopes, which were synthesized simultaneously on a single chip. We also profiled polyclonal antibodies in a total of 1 μl of human serum, revealing patient-specific epitope profiles that are difficult to detect by conventional approaches. By spatially separating gene brushes in the compartment, we extended the gradient approach to reconstitute the interaction of on-chip cell-free expressed human ACE2 receptor with the viral receptor-binding domain in a specific manner. This on-chip genetically programmed approach enables rapid and quantitative interrogation of complex protein-protein interactions, without protein purification steps, for human immuno-profiling and preparedness for emerging pathogens.

Indexed as

Protein Array AnalysisSARS-CoV-2Angiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, ViralAntigens, ViralCell-Free SystemCOVID-19EpitopesHumansLab-On-A-Chip DevicesAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, ViralAntigens, ViralEpitopes

Identifiers

PMID41372446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.